Who is sponsoring NCT04211922?

NCT04211922 is sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

What drugs are being tested in NCT04211922?

Interventions in NCT04211922: Alkotinib Capsules.

What condition does NCT04211922 study?

NCT04211922 studies ALK-positive Non-small Cell Lung Cancer.

Is NCT04211922 still recruiting?

NCT04211922 is currently terminated. Last updated 26 April 2024.

Last reviewed 2024-04-26 · How we verify

NCT04211922

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Terminated Phase 2 Last updated 26 April 2024

What this trial tests

Phase 2 trial testing Alkotinib Capsules in ALK-positive Non-small Cell Lung Cancer in 4 participants. Terminated before completion.

Timeline

21 January 2020

Primary endpoint
11 October 2022

11 October 2022

Quick facts

Lead sponsor	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	21 January 2020
Primary completion	11 October 2022
Estimated completion	11 October 2022
Sites	1 location across China

Drugs / interventions tested

Alkotinib Capsules — full drug profile →

Conditions studied

ALK-positive Non-small Cell Lung Cancer — all drugs for ALK-positive Non-small Cell Lung Cancer →

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd — full company profile →

Who can join

18 and older, any sex, with ALK-positive Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of the study is to evaluate safety and efficacy of Alkotinib capsule in patients with ALK-positive non-small cell lung cancer previously treated with crizotinib.While exploring the relationship between biomarkers and drug efficacy and safety.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting ALK Rearrangements in NSCLC: Current State of the Art.
Peng L, Zhu L, Sun Y, Stebbing J, et al · · 2022 · cited 39× · PMID 35463328 · DOI 10.3389/fonc.2022.863461
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z, Xing Y, Li B, Li X, et al · · 2022 · cited 31× · PMID 36508072 · DOI 10.1186/s43556-022-00107-x
ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies.
Poei D, Ali S, Ye S, Hsu R. · · 2024 · cited 17× · PMID 38835344 · DOI 10.20517/cdr.2024.25
Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
Spitaleri G, Trillo Aliaga P, Attili I, Del Signore E, et al · · 2023 · cited 8× · PMID 37232842 · DOI 10.3390/curroncol30050384

Verify or expand the search:

Other recruiting trials for ALK-positive Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07491497 — A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC · Phase 1, PHASE2 · recruiting
NCT06361589 — Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients · recruiting
NCT04900935 — Patient-centered, Optimal Integration of Survivorship and Palliative Care · NA · recruiting
NCT06410040 — A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis · active not recruiting

Other Suzhou Zelgen Biopharmaceuticals Co.,Ltd trials

Trials by the same sponsor.

NCT05279001 — A Safety and Tolerability Study of Jaktinib · Phase 1 · unknown
NCT06193148 — A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants · Phase 1 · completed
NCT06132243 — Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions · Phase 1 · completed
NCT05864573 — Study of ZGGS15 in Patients With Advanced Solid Tumors · Phase 1 · completed
NCT05584800 — Study of ZGGS18 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04211922 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Last refreshed: 26 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04211922.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing